ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 680

Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus

Christoffer T. Nielsen1, Ole Østergaard2, Line V. Iversen3, Christian Lood4, Anders A. Bengtsson4, Anne Voss5, Søren Jacobsen6 and Niels H. H. Heegaard3, 1Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, 2Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, 3Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 5Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, 6Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, galectin, interferons, systemic lupus erythematosus (SLE) and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Ongoing production of type I interferons (IFN) is a key element in the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs trigger the over-expression of IFN-regulated genes, including galectin-3-binding protein (G3BP). G3BP serves as a scavenger receptor and is a potent immune stimulator. It mediates cellular adhesion and binding to the extracellular matrix of the basement membrane. Thus G3BP may serve as a measure of type I IFNs and has potentially important pathogenic roles in cell-cell interaction and immune complex trafficking in SLE. We here explore the relationship between type I IFN activity and plasma G3BP, compare plasma concentrations of G3BP in two cohorts of SLE patients to patients with systemic sclerosis (SSc) and healthy controls (HCs), and correlate G3BP concentrations with clinical and serological parameters.

 

Methods: Plasma and serum concentrations of G3BP were quantified using a commercially available ELISA. Type I IFN activity was assessed by an Mx1-driven luciferase reporter gene assay. Gene expression scores from 12 genes in peripheral blood mononuclear cells from 26 SLE patients and 10 HCs were compared to plasma concentrations of G3BP. Plasma and serum concentrations were compared in 4 SLE and 4 SSc patient samples. G3BP concentrations in 70 SLE patients were compared to HCs (n =51) and patients with systemic sclerosis (SSc, n =111). Additionally, G3BP levels were validated in an independent cohort of SLE patients (n =67) and HCs (n =50). Non-parametric correlation analyses were used to explore associations between G3BP concentrations and clinical and serological parameters in the two SLE cohorts. In 14 SLE patients consecutive serum samples (3 or 4 per patient, >6 months apart) were analysed and correlated to disease activity (SLEDAI).

 

Results: G3BP plasma concentrations correlated significantly with the Mx-1 driven luciferase reporter gene assay (r =0.56, p =0.0005) and INF-α gene expression scores (r =0.54, p =0.0002). No significant difference between serum and plasma levels of G3BP was observed (p =0.17). Plasma concentrations were similar in the two SLE cohorts (p =0.42) and highly significantly increased compared to HCs and SSc patients (p <0.0001 and 0.0009, both those with diffuse and limited cutaneous disease). Significant associations (p<0.05) with SLEDAI, cell counts, anti-dsDNA, and active nephritis could not be confirmed in the validation cohort. Temporal variations in serum concentrations were observed in the consecutive SLE-samples but were not associated with disease activity (SLEDAI).

 

Conclusion: The level of circulating G3BP is elevated in SLE patients compared with HCs and SSc patients. The SLE-specific elevated levels of G3BP correlated with type I IFN activity. G3BP could thus serve as an easy accessible measure of type I IFN gene activation. Additionally, this study highlights G3BP as an IFN-inducible effector molecule that may have a central role in SLE pathogenesis and thus putatively is a possible new target for therapeutic intervention.


Disclosure:

C. T. Nielsen,
None;

O. Østergaard,
None;

L. V. Iversen,
None;

C. Lood,
None;

A. A. Bengtsson,
None;

A. Voss,
None;

S. Jacobsen,
None;

N. H. H. Heegaard,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-level-of-galectin-3-binding-protein-reflects-type-i-interferon-activity-and-is-highly-increased-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology